(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 11.8% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 15.11%.
Fulgent Genetics's revenue in 2026 is $323,932,000.On average, 3 Wall Street analysts forecast FLGT's revenue for 2026 to be $9,876,339,269, with the lowest FLGT revenue forecast at $9,488,923,944, and the highest FLGT revenue forecast at $10,166,900,764. On average, 3 Wall Street analysts forecast FLGT's revenue for 2027 to be $11,271,089,472, with the lowest FLGT revenue forecast at $10,829,193,866, and the highest FLGT revenue forecast at $11,602,648,752.
In 2028, FLGT is forecast to generate $12,293,007,454 in revenue, with the lowest revenue forecast at $11,727,017,877 and the highest revenue forecast at $12,744,533,412.